Matheson is pleased to have advised Zymeworks on its agreement to acquire Theravance Biopharma, Inc. (“Theravance”) Matheson worked alongside Kirkland & Ellis LLP in advising Zymeworks on this matter.
Theravance is a commercial-stage biopharmaceutical company focused on delivering Medicines that Make a Difference in people’s lives. The acquisition adds YUPELRI, the first and only nebulized, once-daily, long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease to Zymeworks’ partnered portfolio. The acquisition also adds diversified assets beyond YUPELRI, including additional royalty interests, milestone payments and a preclinical immunology and inflammation (“I&I“) portfolio, further strengthening Zymeworks’ potential near-term cash flow generation and long-term development optionality.
The cross-departmental Matheson team was led by Tax partners Gerry Thornton and Philip Tully, Corporate M&A partners David Jones and Brian Butterwick and Finance and Capital Markets partner Maireadh Dale, with support from Employment partner Rachel Barry.
